Rituximab
Steroid, rituximab use can lead to secondary immunodeficiencies
ANAHEIM, Calif. — Use of steroids and B-cell depleting therapies may lead to secondary immunodeficiencies, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
TMP-SMX reduces serious infections ‘by about half’ in patients with GPA using rituximab
SAN DIEGO — Trimethoprim sulfamethoxazole prophylaxis halves serious infection risk in patients with granulomatosis with polyangiitis receiving B-cell depletion with rituximab, according to data presented at ACR Convergence 2023.
What’s in a name? With cancer drugs, more than you might think
When it comes to naming children — at least in my generation — it was pretty straightforward.
PANLAR: Patients with GPA, MPA should use rituximab over cyclophosphamide
Patients with new or relapsing granulomatosis with polyangiitis or microscopic polyangiitis should receive rituximab over cyclophosphamide, according to new recommendations from the Pan American League of Associations for Rheumatology.
FDA clears IND application for ‘allogenic, off-the-shelf’ cell therapy for lupus nephritis
The FDA has cleared an investigational new drug application for AlloNK in combination with rituximab to treat systemic lupus erythematosus in patients with active lupus nephritis, according to a press release from Artiva Biotherapeutics.
VIDEO: Long-term follow up scrutinizes rituximab maintenance for mantle cell lymphoma
In this video, Jakub Svoboda, MD, discusses a study presented at ASCO Annual Meeting that evaluated rituximab maintenance for young patients with mantle cell lymphoma.
VIDEO: Epcoritamab plus R2 ‘showed potent antitumor activity’ in follicular lymphoma
CHICAGO - In this video, Reid Merryman, MD, discusses updates on a trial testing the combination of epcoritamab, rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma.
Rituximab, cyclophosphamide show similar rates of kidney failure, death in AAV
Remission induction strategies based on rituximab and cyclophosphamide each demonstrate similar risks for kidney failure and death in patients with ANCA-associated vasculitis, according to data published in Arthritis & Rheumatology.
Split-dose R-CHOP regimen effective for older adults with newly diagnosed lymphoma
CHICAGO — A split-dose approach to the standard R-CHOP chemotherapy regimen resulted in a 71% complete response rate among older adults with newly diagnosed diffuse large B-cell lymphoma, results from a phase 2 study showed.
Central nervous system vasculitis treatment strategies still lack strong data
Current treatment strategies for patients with central nervous system vasculitis are not based on high-grade scientific evidence but rather expert opinion, according to a speaker at the Biologic Therapies Summit.